Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
163.02B
Market cap163.02B
Price-Earnings ratio
17.87
Price-Earnings ratio17.87
Dividend yield
2.43%
Dividend yield2.43%
Average volume
6.89M
Average volume6.89M
High today
$133.34
High today$133.34
Low today
$129.00
Low today$129.00
Open price
$130.00
Open price$130.00
Volume
10.15M
Volume10.15M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$96.19
52 Week low$96.19

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $131.10. The company's market cap stands at 163.02B, with a P/E ratio of 17.87 and a dividend yield of 2.4%.

As of 2026-05-10, Gilead Sciences(GILD) stock has fluctuated between $129.00 and $133.34. The current price stands at $131.10, placing the stock +1.6% above today's low and -1.7% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 10.15M, against a daily average of 6.89M.

During the past year, Gilead Sciences(GILD) stock moved between $96.19 at its lowest and $157.29 at its peak.

During the past year, Gilead Sciences(GILD) stock moved between $96.19 at its lowest and $157.29 at its peak.

GILD News

TipRanks 2d
Gilead Sciences Balances Strong Growth With EPS Hit

Gilead Sciences ((GILD)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and pow...

Nasdaq 2d
Gilead Q1 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Gilead Q1 2026 Earnings Call Transcript
Investor's Business Daily 3d
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy

Gilead stock toppled late Thursday after the drugmaker issued a mixed guidance despite beating first-quarter sales expectations on the back of its HIV drugs Bik...

Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More GILD News

Simply Wall St 3d
A Look At Gilead Sciences Valuation After FDA Priority Review For New HIV Tablet

Gilead Sciences (GILD) recently drew attention after the FDA accepted its New Drug Application for a once daily bictegravir and lenacapavir HIV tablet. The appl...

A Look At Gilead Sciences Valuation After FDA Priority Review For New HIV Tablet
Benzinga 3d
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings for its first quarter after the closing bell on Thursday, May 7. Analysts expect the Foster City, Cal...

Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
TipRanks 6d
Gilead Shareholders Back Board, Pay Plans at 2026 Meeting

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 6d
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences?

On 20 April 2026, Arcus Biosciences and Gilead Sciences discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies in metastatic non-small cell lung cancer...

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences?

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.